Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

96.85 -1.27 (-1.29%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Abbott Laboratories

< Previous 1 2 3 4 5 Next >
2 Stocks to Benefit from the Aging Population
The growth of the aging population is entirely predictable, which makes now an ideal time to consider these two health and wellness stocks 
Via MarketBeat
Topics Retirement
Exposures COVID-19 Pension
Less Is More: Abbott’s Approach to Packaging Innovation
Via ACCESSWIRE
Abbott Joins Billion Dollar Roundtable
Via ACCESSWIRE
A Significant Reversal is in Sight for These 5 Med Tech Companies
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand. 
Via MarketBeat
5 Good Reasons it's Time to Buy High-Yield Dividend King 3M
3M settled the ear plug lawsuit, clearing the path forward. The stock offers investors a high yield and value that may be too hard to pass up 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Abbott Laboratories (NYSE: ABT) is a Leading Gainer in Wednesday Morning Trading
Via Investor Brand Network
Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher
Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans. 
Via MarketBeat
Johnson & Johnson's Inflection Point: What it Means for Investors
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories Has the Prescription for Higher Share Prices
Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating. 
Via MarketBeat
Exposures COVID-19
Agilent Technologies Stock: Ready to Rise off the Floor
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider. 
Via MarketBeat
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next. 
Via MarketBeat
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning 
Via MarketBeat
Exposures COVID-19 Product Safety
Can Boston Scientific Set Another Net High?
Boston Scientific issued a stellar report and gave favorable guidance, but the stock is having difficulty moving higher and may move sideways in the near term. 
Via MarketBeat
Diversified Abbott Laboratories Could Reverse And Move Higher
Abbott Laboratories reported a solid quarter driven by gains in the core business that are accelerating as COVID sales decline. 
Via MarketBeat
Exposures COVID-19
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat
ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT
From Kahn Swick & Foti, LLC
Via Business Wire
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its 
Via MarketBeat
Topics Initial Public Offering
Exposures COVID-19 Product Safety Securities Market
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
From Brodsky & Smith LLC
Via GlobeNewswire
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)
From Brodsky & Smith LLC
Via GlobeNewswire
Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million
Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and 
Via Spotlight Growth
GE Healthcare Technology: Speculating On Dividends
GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one. 
Via MarketBeat
Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
Is Medtronic Stock Ready to Revive?
The world’s largest medical device maker Medtronic PLC (NYSE: MDT) stock has fallen since April 2022. However, shares may have bottomed out. 
Via MarketBeat
Topics Economy
Exposures Interest Rates Supply Chain
Two Blue Chip Health Companies The Institutions Are Buying
Johnson & Johnson and Abbott Laboratories are two Dividend Kings the analysts are buying, one stock is ready to rebound and the other to lead the market. 
Via MarketBeat
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. 
Via MarketBeat
Topics Death
Exposures COVID-19 Death
Intuitive Surgical Stock is Both a Legacy and Next-Gen Play
It’s hard to believe that the da Vinci Surgical System developed by Intuitive Surgical (NASDAQ: ISRG) is turning 22 years old since its U.S. Food and Drug 
Via MarketBeat
Topics Economy
Exposures COVID-19 Interest Rates Supply Chain
NYSE: ABT Investor Notice: Deadline on October 31, 2022 in Lawsuit Against Abbott Laboratories
San Diego, CA -- (SBWIRE) -- 10/31/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 31, 2022 in the lawsuit filed for certain investors of Abbott Laboratories... 
Via SBWire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.